Axogen, Inc. (AXGN)
Sector: Electromedical & Electrotherapeutic Apparatus
Industry: Medical - Devices
AxoGen, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | 48.55 | 50.29 | 48.14 | 50.02 | 1,665,716 |
| Nov 5, 2026 | 51.62 | 51.85 | 47.57 | 48.75 | 1,210,102 |
| Nov 4, 2026 | 50.28 | 52.74 | 50.08 | 51.35 | 1,865,979 |
| Nov 3, 2026 | 50.49 | 50.84 | 49.18 | 49.50 | 1,046,432 |
| Nov 2, 2026 | 49.46 | 50.54 | 49.04 | 49.85 | 1,960,354 |
| Oct 30, 2026 | 49.70 | 49.88 | 48.08 | 49.37 | 1,835,156 |
| Oct 29, 2026 | 49.61 | 51.16 | 48.39 | 49.63 | 2,280,989 |
| Oct 28, 2026 | 45.45 | 49.97 | 43.50 | 49.25 | 9,290,559 |
| Oct 27, 2026 | 38.14 | 39.03 | 37.23 | 37.46 | 2,461,145 |
| Oct 26, 2026 | 38.06 | 38.71 | 37.71 | 38.02 | 1,021,725 |
| Oct 23, 2026 | 36.64 | 38.33 | 36.60 | 38.06 | 2,192,083 |
| Oct 22, 2026 | 36.48 | 37.29 | 36.21 | 36.68 | 961,632 |
| Oct 21, 2026 | 36.01 | 37.47 | 36.00 | 36.48 | 1,131,528 |
| Oct 20, 2026 | 35.71 | 36.84 | 35.56 | 36.17 | 974,619 |
| Oct 19, 2026 | 34.86 | 35.26 | 34.11 | 35.24 | 782,538 |
| Oct 16, 2026 | 35.63 | 35.65 | 34.40 | 34.62 | 1,143,188 |
| Oct 15, 2026 | 35.14 | 36.42 | 35.14 | 35.63 | 986,003 |
| Oct 14, 2026 | 35.91 | 36.55 | 35.03 | 35.14 | 1,173,575 |
| Oct 13, 2026 | 37.20 | 37.40 | 35.83 | 36.17 | 2,136,617 |
| Oct 12, 2026 | 36.80 | 37.30 | 35.72 | 37.11 | 1,606,549 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Director | Sale | 3.5K | $173.9K | Sep 2, 2026 | |
| Director | Option Exercise | 13.4K | $198.3K | Aug 11, 2026 | |
| Director | Option Exercise | 13.4K | -- | Aug 11, 2026 | |
| Director | Sale | 13.4K | $646.6K | Aug 11, 2026 | |
| EVP & General Counsel | Option Exercise | 67.5K | $550.8K | Aug 10, 2026 | |
| EVP & General Counsel | Option Exercise | 67.5K | -- | Aug 10, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
BlackRock, Inc. | 4.4M | 7.4% | 13F |
Divisadero Street Capital Management, LP · net of 13F· joint filing· may incl. warrants· filed Oct 2026 | 4.0M | 6.7% | 13G |
Mathew P. Arens · also on 13F· joint filing· may incl. warrants· filed May 2026 | 3.6M | 6.1% | 13G |
First Light Asset Management, LLC | 2.7M | 4.6% | 13F |
MORGAN STANLEY | 2.7M | 4.6% | 13F |
Vanguard Capital Management · also on 13F· may incl. warrants· filed Jul 2026 | 2.7M | 4.4% | 13G |
Morgan Stanley · also on 13F· may incl. warrants· filed Feb 2025 | 2.3M | 3.9% | 13G |
VANGUARD CAPITAL MANAGEMENT LLC | 2.3M | 3.8% | 13F |
Artemis Investment Management LLP | 1.8M | 3.0% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 1.6M | 2.8% | 13F |
Insiders
- TYNDALL JOSEPH A.Director
- Wendell Amy McBrideDirector
- Began Marc AEVP & General Counsel
- Weiler Kathy JohnsonDirector
- Levine Alan MDirector
- Burke William P. Mr.Director
- THOMAS PAULDirector
- JOHNSON JOHNDirector
- Hartley Lindsey MarieCFO
- Quackenbush DorisSales VP
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally.
The company's main operations are situated in Alachua, Florida.
based on 59.73M shares outstanding
30d Avg
1.89M
60d Avg
1.71M
90d Avg
1.45M